Henglu Biotech Has 3 International Firsts and 4 Domestic Firsts
Synthetic biology production of HMOs is safer, more efficient, and more commercially advantageous
The world's first mass production of HMOs by yeast/enzyme
The first in the world to achieve mass production of LNT, LNTII and LNB crystallization processes, with a purity of over 99%
The first in the world to achieve mass production of lacto-N-triose, one of the important components of HMO
The first Chinese company to complete the food safety experiment of HMO
The first Chinese company to apply for HMO approval from the National Health Commission
The first Chinese national enterprise to develop HMO
The first Chinese/Australian invention patent authorized by a Chinese national enterprise in the field of HMO
Core Patent
Synthetic biology production of HMOs is safer, more efficient, and more commercially advantageous
Patent Layout
Obtain national patent authorization and PCT international patent application in Europe, America, Australia, New Zealand and other regions and national invention patents in 2020;
It is the only non-foreign investment in China that has obtained the patent authorization of HMOs by enzymatic preparation process: it has initially completed the layout of domestic and foreign patents: it has solved the “bottleneck” technical problem in my country and filled the domestic gap.
![]()
Innovative Technology Path
Synthetic biology production of HMOs is safer, more efficient, and more commercially advantageous
- ● More concise and efficient phosphorylation synthesis pathway;
- ● Overturn the traditional biosynthetic pathway of UDP sugar derivatives in Europe, America and Japan;
- ● Form the core technology of HMOs with independent intellectual property rights;
- ● Enzymatic synthesis of HMOs;
- ● Overturn the transgenic technology of Escherichia coli as the host of European and American companies;
- ● It is more in line with the requirements of Chinese food regulations and has no risk of endotoxin.
"Biosmart" Artificial Intelligence R&D Platform
Artificial Intelligence｜Enzyme Component Library｜High Throughput Screening｜Protein Design｜Molecular Docking
Expert Introduction
Synthetic biology production of HMOs is safer, more efficient, and more commercially advantageous
PharmD of Shizuoka University, Japan;
Vice President of Japan Enzyme Engineering Society;
R&D Director of Amano Enzyme Co., Ltd.;
40 Years of Experience in the Development and Preparation of Bioengineering Enzyme Preparations/Enzymes
National High-level Talent Youth Plan Expert;
Professor and Doctoral Supervisor of Tianjin University;
Postdoc at the University of Illinois at Urbana-Champaign;
Kluyveromyces Expert;
Associate Professor, School of Life Sciences, University of Science and Technology of China;
Ph.D. of Kyoto University, Japan; Postdoc of Kyoto University and Virginia Tech;
Special Allowance Expert of the State Council;
Taishan Industry Leading Talents;
Former Chief Scientist and R&D Director of DISA Pharmaceuticals;
30 years of Experience in Research and Development of Pharmaceutical Preparations